Company intelligence / Profile preview

Novus Scientific

Ownership: Private
Development stage: Commercial

Overview

Novus Scientific has developed and commercialized the TIGR Matrix, the world’s first long-term resorbable surgical mesh for soft tissue reinforcement. The product is used globally by surgeons with a growing body of clinical evidence supporting its safety and efficacy in various soft tissue repair procedures[3].

Therapeutic areas: OtherGastroenterology
Modalities: DeviceBiomaterial-based therapyResorbable surgical mesh (polymer-based medical device)
Industry: Surgical Medical Devices

Drug pipeline

1 asset

TIGR Matrix

Commercial

Indications: Soft tissue reinforcement, Hernia repair, Abdominal wall reconstruction

Partnerships

None specifically mentioned in public sources as of June 2025.

Beyond the preview

Go deeper on Novus Scientific.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Novus Scientific.

Explore the full profile